Evidence map›Paper›PMID 39639015›Full record

ArticleNPJ Regenerative medicine2024

Attenuation of skin injury by a MARCO targeting PLGA nanoparticle.

Ummiye V Onay, Dan Xu, Dauren Biyashev, Spencer T Evans, Michael M Demczuk, Tobias Neef, Joseph R Podojil, Sara Beddow, Nathan C Gianneschi, I Caroline Le Poole and 2 more

Abstract read
In one paragraph

Article in NPJ Regenerative medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ummiye V Onay *Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-0103-2376
Dan Xu *Department od Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-5315-8552
Dauren BiyashevDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0009-0005-9014-9654
Spencer T EvansDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-2036-5704
Michael M DemczukDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0009-0006-6209-4120
Tobias NeefDepartment od Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Joseph R PodojilDepartment od Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Sara BeddowDepartment od Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Nathan C GianneschiDepartment of Chemistry, Northwestern University, Evanston, IL, USA.ORCID http://orcid.org/0000-0001-9945-5475
I Caroline Le PooleDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Stephen D MillerDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. s-d-miller@northwestern.edu.ORCID http://orcid.org/0000-0002-9556-0718
Kurt Q LuDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. kurt.lu@northwestern.edu.ORCID http://orcid.org/0000-0002-8297-433X

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9M
Translation & trials: advancing medical countermeasure developmentU54AR079795 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LU, KURT · 2021 to 2024
$10.9M
Northwestern University Skin Disease Research Center Resource-based CenterP30AR075049 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Irina Budunova · 2019 to 2026
$6.6M
Translation of novel and repurposed drugs to address the acute and late effects of mustard exposureU01AR071168 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LU, KURT · 2017 to 2021
$4.1M
NCI NIH HHS P30 CA060553NIAMS NIH HHS P30 AR075049NIAMS NIH HHS U01 AR071168NIAMS NIH HHS U54 AR079795U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) U54 AR0797905
6 · The paper itself

Abstract

Cutaneous exposure to the DNA alkylating class of chemotherapeutic agents including nitrogen mustard (NM) leads to both skin injury and systemic inflammation. Circulating myeloid subsets recruited to the skin act to further exacerbate local tissue damage while interfering with the wound healing process. We demonstrate herein that intravenous delivery of poly(lactic-co-glycolic acid) immune-modifying nanoparticles (PLGA-IMPs) shortly after NM exposure restricts accumulation of macrophages and inflammatory monocytes at the injury site, resulting in attenuated skin pathology. Furthermore, PLGA-IMPs induce an early influx and local enrichment of Foxp3

Identifiers

PMID39639015
PMCPMC11621362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.